JUL 12, 2016 12:57 PM PDT

PDE4B Inhibitor to Treat Traumatic Brain Injury

WRITTEN BY: Cassidy Reich
Traumatic brain injuries (TBI) are the leading cause of death and disability for Americans under the age of 45. Specifically, 5 million people in the U.S. are living with a chronic disability due to a TBI. There is currently no effective drug to help those with TBI, but there is a great demand for some such therapeutic. Not only would an effective TBI therapeutic restore the learning and memory deficits in those affected, but would lower the cost of TBIs, which currently stands at the astounding number of $76.5 billion annually.


As you might imagine from the name “traumatic brain injury,” a TBI is caused by an impact to the head. TBIs by themselves can be fatal, but of those who survive, ~80% experience problems with learning and memory in the months and years after the trauma. Drugs such as Ritalin (methylphenidate) and Aricept (donepezil) are sometimes used to help manage the deficits, but neither one treats the underlying cause. Both drugs, though they operate on different neurotransmitter systems, functional similarly in that they increase attention and paying attention is the first step in learning and memory. However, they do not affect the downstream processes of memory formation.

A recent effort between the University of Miami and The Miami Project to Cure Paralysis determines the brain changes that occur in the months after a TBI that affect learning and memory and also tests a drug candidate to correct these changes. The paper, entitled “Chronic Cognitive Dysfunction after Traumatic Brain Injury is Improved with a Phosphodiesterase 4B Inhibitor,” was recently published in The Journal of Neuroscience.

The researchers induced TBI in rats and left them untreated for 3 months before looking for changes in the brain. What they found was decreased levels of 2 proteins, cAMP and CREB, that are crucial for learning and memory formation. In a healthy, non-traumatized brain, neuronal activity elevates cAMP levels which in turn activates CREB to strengthen synaptic connections, induce long term potentiation, and form memories.

By using a very specific enzyme inhibitor, the researchers hoped to inhibit the degradation of cAMP to increase the amount available to activate CREB. This strategy has been tried in the past, but with less specific inhibitors that caused undesirable effects. The use of a specific phosphodiesterase 4B inhibitor (PDE4B inhibitor) instead of a pan-PDE4 inhibitor looks very promising in the rat model of TBI. 3 months after an untreated TBI, administration of the specific PDE4B inhibitor restored memory deficits in the injured rats to nearly non-injured levels without causing the side effects of emesis and diarrhea.

The PDE4B inhibitor used in the study is in the company Tetra Discovery’s pipeline and is being tested for other indications as well. There is hope that this specific PDE4B inhibitor can be used for other neurological disorders such as schizophrenia and depression. Some kind of therapeutic for the learning and memory deficits in TBI is needed, and Tetra’s compound looks like a good start.

Sources: FierceBiotech and PR Newswire
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
DEC 21, 2020
Microbiology
The Food Mom Eats Affects the Microbes in Her Breast Milk
DEC 21, 2020
The Food Mom Eats Affects the Microbes in Her Breast Milk
Although baby formula is a completely acceptable alternative for women that have trouble lactating, human milk is still ...
DEC 29, 2020
Immunology
Cancer-Killing Viruses Enter in Stealth Mode, Penetrate Immune Barrier
DEC 29, 2020
Cancer-Killing Viruses Enter in Stealth Mode, Penetrate Immune Barrier
Viruses that when administered to patients preferentially attack and kill cancer cells, leaving normal tissues unscathed ...
DEC 28, 2020
Cancer
Revealing a Critical Protein Involved in the Pentose Phosphate Pathway in Cancer
DEC 28, 2020
Revealing a Critical Protein Involved in the Pentose Phosphate Pathway in Cancer
The metabolism of cancer has interested scientists in recent decades. Many cancers conduct "normal" metabolism ...
DEC 29, 2020
Clinical & Molecular DX
Injectable Heart Health Tracker Now Picks Up COVID Red Flags
DEC 29, 2020
Injectable Heart Health Tracker Now Picks Up COVID Red Flags
The statistics are a real eye-opener: in the United States, one person dies every 36 seconds from cardiovascular disease ...
JAN 11, 2021
Genetics & Genomics
Treating Progeria With a CRISPR Technique
JAN 11, 2021
Treating Progeria With a CRISPR Technique
Hutchinson-Gilford progeria syndrome is a rare disorder that impacts around 400 people in the world. Many people have he ...
JAN 19, 2021
Immunology
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
JAN 19, 2021
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
Milk, eggs, peanuts, tree nuts, wheat, soy, fish, and shellfish—these foods are among the most unwanted list for t ...
Loading Comments...